Merck Tops Q3 Estimates as Keytruda and Gardasil Drive Growth
Merck beat Q3 forecasts with $18.1B sales and $2.49 EPS. Keytruda and Gardasil powered results as the company raised its full-year outlook.
/ 41 items
#MRK↓
Potential Data Leak Hits Moderna, Merck Ahead of Cancer Vaccine Presentation
TD Cowen calls Phase 3 intismeran + Keytruda results “compelling” and in the exceptional range. Wells Fargo says RFS exceeded expectations.
Hotter CPI Hits Stocks, but Big Pharma Defies the Slide
Eli Lilly, Merck, AbbVie, and UnitedHealth rose as markets fell on stronger inflation data, highlighting healthcare’s defensive strength.
VAX-31 Meets Phase 3 Goals, Putting Vaxcyte’s 31-Strain Pneumococcal Shot on a 2028 Filing Path
Vaxcyte shares surged after VAX-31 met adult Phase 3 goals versus Prevnar 20 and Capvaxive. A BLA filing is targeted for the first half of 2028.
Merck’s HS Data Validates the TL1A Pathway — and Helps Shattuck Labs
Merck’s tulisokibart met its Phase 2b HS goal and will move to Phase 3. H.C. Wainwright sees first anti-TL1A skin data as a class plus for Shattuck.
Citi Says Moderna Looks Too Expensive After Cancer-Vaccine Rally
Citi says Moderna’s rally after the INTerpath-001 melanoma win pushed its market value near Regeneron’s despite weaker near-term earnings.